Electra Therapeutics raised $350 million in one of the larger biotechnology IPOs of 2026, but investors immediately marked down the clinical-stage drug developer as its shares fell nearly 12% in their first day of Nasdaq trading.
Electra priced 23.33 million shares at $15 each Thursday night, the midpoint of its $14-to-$16 range and above the 21.67 million shares originally planned. The upsized offering valued the company at roughly $941 million at the IPO price.
Shares opened Friday at $15, briefly reached $15.50 and then closed at $13.25, down 11.7%. That left Electra with a market capitalization of roughly $832 million after its first trading session.
The contrast is notable.
Institutional demand was strong enough for Electra to increase the size of the deal before pricing, but the stock could not hold the offering price once public trading began.
Electra is not selling investors an existing revenue stream. It has no approved products, has never generated product revenue and expects continued losses while it develops its pipeline.
Nearly everything depends on whether its lead antibody, ipsoprubart, can turn unusually strong results from a very small early study into a successful registrational trial.
A $350 Million Bet on One Lead Drug
Ipsoprubart, formerly known as ELA026, is being developed primarily for secondary hemophagocytic lymphohistiocytosis, or sHLH.
The rare condition occurs when immune cells become dangerously overactivated, producing severe inflammation that can rapidly damage organs and become fatal. It can be triggered by cancers, infections, autoimmune disorders and certain therapies.
Electra designed ipsoprubart to target signal regulatory proteins, or SIRPs, expressed at elevated levels on activated T cells and myeloid cells.
Rather than broadly suppressing the immune system, the antibody is intended to selectively eliminate disease-driving activated cells while preserving more normal immune populations.
Early results are why Electra has been able to attract substantial capital.
In a Phase 1b study, 12 previously untreated patients with malignancy-associated HLH had an eight-week overall survival rate of 100%. All 12 also achieved an overall response, including 10 partial responses and two modified complete responses.
Those results are encouraging in a disease associated with high mortality, but 12 patients remain a very small dataset.
There was also no randomized control arm.
Electra is now testing ipsoprubart in SURPASS, a global Phase 2/3 registrational study enrolling newly diagnosed patients. The trial uses an external control group derived partly from the company’s COMPASS natural-history study rather than randomly assigning patients to a conventional control arm.
The study’s primary endpoint is eight-week survival in treatment-naïve patients with lymphoma-associated HLH.
Enrollment is expected to finish during the second half of 2027.
Until significantly more patients are treated, the market has little evidence that the near-perfect response seen in the small Phase 1b population will persist in a broader group.
The FDA has granted ipsoprubart Breakthrough Therapy designation, while the European Medicines Agency has awarded it PRIME status. Those designations can accelerate development and regulatory interaction but do not guarantee approval.
Most of the IPO Money Is Going Into Ipsoprubart
Electra’s capital allocation makes the concentration clear.
The company plans to use roughly $220 million to advance ipsoprubart through the SURPASS program, regulatory preparations and activities supporting a potential approval application.
Another $25 million is earmarked for an ongoing Phase 1 study of ipsoprubart in relapsed or refractory T-cell and natural-killer-cell malignancies.
About $50 million is expected to support ELA822, Electra’s second clinical candidate.
ELA822 targets SIRPγ more selectively than ipsoprubart and is being developed for chronic T-cell-mediated immune and inflammatory diseases. Electra recently began a Phase 1 trial in healthy volunteers and eventually plans to move the drug into patients.
The upsized IPO materially strengthens Electra’s balance sheet.
The company held $97.7 million of cash, cash equivalents and marketable securities at June 30. The final offering is expected to generate roughly $325.5 million after underwriting discounts but before other offering expenses, pushing pro forma cash and investments above $400 million.
Management expects its available capital to fund operations into 2029.
That runway reduces near-term financing pressure but does not eliminate it.
Electra explicitly warns that its current resources are not expected to cover the full development and commercialization of its pipeline. Additional financing could eventually be required, particularly if ipsoprubart succeeds and the company begins preparing for a commercial launch.
Losses Are Rising With Clinical Spending
Electra’s expenses have already increased substantially as the pipeline advances.
The company lost $62 million in 2025, up from a $24.8 million loss in 2024.
During the first six months of 2026, its net loss widened to $48.9 million from $25.4 million a year earlier. Research and development expenses more than doubled as SURPASS and other clinical programs expanded.
Electra had accumulated a $221.9 million deficit by the end of June.
None of that is unusual for a late-stage biotechnology company.
It does mean conventional earnings metrics offer little help in determining what Electra is worth.
The valuation instead rests largely on clinical probabilities: how likely ipsoprubart is to reproduce its early results, complete SURPASS successfully, win regulatory approval and eventually establish a commercially viable market in sHLH.
ELA822 and the company’s oncology programs provide additional potential value, but they are earlier in development.
The First-Day Drop Shows Where Investors See the Risk
Electra’s IPO arrived during a stronger year for biotechnology listings, with investors returning to clinical-stage companies after a more difficult funding environment.
The deal itself demonstrated that appetite.
Electra initially proposed selling about 21.67 million shares. It ultimately sold 23.33 million while still pricing at the $15 midpoint, increasing the offering to $350 million.
Then the shares fell immediately.
The 11.7% first-day decline reduced roughly $110 million from Electra’s equity value compared with the valuation established at the IPO price.
That does not change the amount of capital Electra raised. The company still receives its IPO proceeds.
It does change the valuation new public shareholders are willing to assign to the pipeline.
At $13.25, the market is effectively demanding a larger discount for clinical risk than investors who bought the IPO at $15.
That skepticism is understandable because the company’s most compelling clinical evidence comes from only 12 frontline patients, while the trial intended to support approval is still enrolling.
The next major milestones therefore matter considerably more than quarterly revenue or earnings.
Electra expects SURPASS enrollment to finish in the second half of 2027. Initial clinical data from the separate ipsoprubart trial in T-cell and NK-cell malignancies are also expected during the second half of 2027.
For ELA822, investors will first be looking for safety and pharmacology data that support moving from healthy volunteers into patients.
Until those datasets arrive, Electra has something many young biotechs lack: more than $400 million of pro forma capital and enough runway to reach important clinical milestones without immediately returning to shareholders for money.
What it does not yet have is confirmation that the extraordinary early response seen with ipsoprubart will survive the transition from 12 patients to a registrational trial.
Friday’s 12% decline shows that public investors are already pricing that uncertainty into the stock.